1-20 of 54
molecular targeted therapy
Close
Sort by
Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.
https://doi.org/10.1182/hematology.2019000006
Published: 2019
Journal Articles

Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials

Jennifer A. Woyach
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 476–481.
https://doi.org/10.1182/hematology.2019001321
Published: 2019
Journal Articles

Where does transplant fit in the age of targeted therapies?

Victor A. Chow, Ajay K. Gopal
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 287–293.
https://doi.org/10.1182/hematology.2019000033
Published: 2019
Journal Articles

Treatments targeting MDS genetics: a fool’s errand?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 277–285.
https://doi.org/10.1182/asheducation-2018.1.277
Published: 2018
Journal Articles

Challenges and implications of genomics for T-cell lymphomas

Eric D. Jacobsen, David M. Weinstock
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 63–68.
https://doi.org/10.1182/asheducation-2018.1.63
Published: 2018
Journal Articles

Relapsed CLL: sequencing, combinations, and novel agents

Jennifer R. Brown
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 248–255.
https://doi.org/10.1182/asheducation-2018.1.248
Published: 2018
Journal Articles

New drugs for acute myeloid leukemia inspired by genomics and when to use them

Daniel A. Pollyea
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 45–50.
https://doi.org/10.1182/asheducation-2018.1.45
Published: 2018
Journal Articles

Progress in adult ALL: incorporation of new agents to frontline treatment

Jessica Leonard, Wendy Stock
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 28–36.
https://doi.org/10.1182/asheducation-2017.1.28
Published: 2017
Journal Articles

The role of targeted therapy in the management of patients with AML

Alexander E. Perl
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 54–65.
https://doi.org/10.1182/asheducation-2017.1.54
Published: 2017
Journal Articles

Clinical implications of somatic mutations in aplastic anemia and myelodysplastic syndrome in genomic age

Jaroslaw P. Maciejewski, Suresh K. Balasubramanian
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 66–72.
https://doi.org/10.1182/asheducation-2017.1.66
Published: 2017
Journal Articles

AL amyloidosis: from molecular mechanisms to targeted therapies

Giampaolo Merlini
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 1–12.
https://doi.org/10.1182/asheducation-2017.1.1
Published: 2017
Journal Articles

Prognostic factors in follicular lymphoma: new tools to personalize risk

Carla Casulo
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 269–276.
https://doi.org/10.1182/asheducation-2016.1.269
Published: 2016
Journal Articles

First-line therapy for young patients with CLL

Nitin Jain, Susan O’Brien
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 146–148.
https://doi.org/10.1182/asheducation-2016.1.146
Published: 2016
Journal Articles

Prognostication of chronic lymphocytic leukemia in the era of new agents

Barbara Eichhorst, Michael Hallek
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 149–155.
https://doi.org/10.1182/asheducation-2016.1.149
Published: 2016
Journal Articles

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies

E. Anders Kolb, Soheil Meshinchi
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 507–513.
https://doi.org/10.1182/asheducation-2015.1.507
Published: 2015
Journal Articles

Molecularly targeted therapies for acute myeloid leukemia

Eytan M. Stein
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 579–583.
https://doi.org/10.1182/asheducation-2015.1.579
Published: 2015
Journal Articles

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Amy E. DeZern
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 308–316.
https://doi.org/10.1182/asheducation-2015.1.308
Published: 2015
Journal Articles

Treatment of Langerhans cell histiocytosis: role of BRAF/MAPK inhibition

Oussama Abla, Sheila Weitzman
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 565–570.
https://doi.org/10.1182/asheducation.V2015.1.565.3919688
Published: 2015
Journal Articles

Uncommon histiocytic disorders: Rosai–Dorfman, juvenile xanthogranuloma, and Erdheim–Chester disease

Julien Haroche, Oussama Abla
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 571–578.
https://doi.org/10.1182/asheducation.V2015.1.571.3916289
Published: 2015
Journal Articles

Advances in therapies for non-Hodgkin lymphoma in children

Rachel Kobos, William Terry
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 522–528.
https://doi.org/10.1182/asheducation.V2015.1.522.3916185
Published: 2015